We also demonstrated a significantly improved effect from combination therapy with DHA and sorafinib or sunitinib, indicating the feasibility of DHA as a sensitizer for PDGFR-targeted therapy for ovarian cancer patients. This evidence concerns the gene PDGFRB and ovarian carcinoma.